FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

cotellic
(COBIMETINIB)
Genentech, Inc.
Usage: COTELLIC® is indicated for adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, in combination with vemurafenib. It is also indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.
mektovi
(BINIMETINIB)
Array BioPharma Inc.
Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.
opdivo
(nivolumab)
E.R. Squibb & Sons, L.L.C.
Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.
proleukin
(aldesleukin)
Clinigen Limited
Usage: Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC) and metastatic melanoma.
tafinlar
(dabrafenib)
Novartis Pharmaceuticals Corporation
Usage: TAFINLAR is indicated for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, non-small cell lung cancer, anaplastic thyroid cancer, solid tumors, and low-grade glioma in patients aged one year and older. It should not be used in colorectal cancer or wild-type BRAF tumors.
zelboraf
(Vemurafenib)
Genentech, Inc.
Usage: ZELBORAF® is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and for Erdheim-Chester Disease (ECD) with the same mutation. It is not suitable for patients with wild-type BRAF melanoma.

Medications for Metastatic Melanoma

cotellic

mektovi

opdivo

proleukin

tafinlar

zelboraf